• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD146介导的干性表型获得增强了肺癌表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药后的肿瘤侵袭和转移。

CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer.

作者信息

Zhang Fan, Wang Jia, Wang Xiaobo, Wei Nan, Liu Haiyang, Zhang Xiaoju

机构信息

Department of Respiratory Medicine, Henan Provincial People's Hospital, Zhengzhou, Henan, China.

Clinical Research Center, Henan Provincial People's Hospital, Zhengzhou, Henan, China.

出版信息

Clin Respir J. 2019 Jan;13(1):23-33. doi: 10.1111/crj.12976.

DOI:10.1111/crj.12976
PMID:30480362
Abstract

INTRODUCTION

Tumours are more likely to metastasize after the development of resistance to EGFR-TKIs. CD146 is a multifunctional molecule and is implicated in tumour invasion and metastasis; however, its role in lung cancer has not been clearly established.

OBJECTIVE

Here, we aimed to explore the relationship between CD146 pathway and stem cell phenotype after EGFR-TKI resistance in lung cancer.

METHODS

EGFR-TKI-resistant cell lines were established by exposing parental cells to erlotinib/gefitinib. The CD146 level was measured by a western blot, RT-PCR and immunocytochemistry fluorescent. Cell migration was examined by the transwell assay and the scratch assay. Stemness phenotype genes were evaluated by RT-PCR and stem cell phenotype was observed by the microsphere formation assay.

RESULTS

CD146 and stemness phenotype genes increased while β-catenin decreased in acquired EGFR-TKI-resistant cell lines. CD146's over-expression induced the up-regulation of stemness-related genes and was inversely correlated with the β-catenin expression, which further increased the migration capability of resistant cancer cells. CD146's knockdown suppressed cell migration and stemness phenotype.

CONCLUSIONS

CD146 molecule contributes to the stemness phenotype and migration in EGFR-TKI-resistant cells. CD146 might be a potential therapeutic target for EGFR-TKI-resistant lung cancer or metastasis prevention.

摘要

引言

肿瘤在对表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)产生耐药性后更易发生转移。CD146是一种多功能分子,与肿瘤侵袭和转移有关;然而,其在肺癌中的作用尚未明确。

目的

在此,我们旨在探讨肺癌中EGFR-TKI耐药后CD146通路与干细胞表型之间的关系。

方法

通过将亲本细胞暴露于厄洛替尼/吉非替尼来建立EGFR-TKI耐药细胞系。通过蛋白质免疫印迹法、逆转录-聚合酶链反应(RT-PCR)和免疫细胞化学荧光法检测CD146水平。通过Transwell实验和划痕实验检测细胞迁移。通过RT-PCR评估干性表型基因,并通过微球形成实验观察干细胞表型。

结果

在获得性EGFR-TKI耐药细胞系中,CD146和干性表型基因增加,而β-连环蛋白减少。CD146的过表达诱导干性相关基因上调,并与β-连环蛋白表达呈负相关,这进一步增加了耐药癌细胞的迁移能力。CD146的敲低抑制了细胞迁移和干性表型。

结论

CD146分子有助于EGFR-TKI耐药细胞的干性表型和迁移。CD146可能是EGFR-TKI耐药肺癌或预防转移的潜在治疗靶点。

相似文献

1
CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer.CD146介导的干性表型获得增强了肺癌表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药后的肿瘤侵袭和转移。
Clin Respir J. 2019 Jan;13(1):23-33. doi: 10.1111/crj.12976.
2
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.厄洛替尼或吉非替尼治疗铂类预处理复发的非小细胞肺癌和卵巢癌:系统评价。
Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24.
3
Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.厄洛替尼联合转化生长因子-β Ⅰ型受体抑制剂有效抑制厄洛替尼耐药非小细胞肺癌细胞迁移能力增强。
J Thorac Oncol. 2013 Mar;8(3):259-69. doi: 10.1097/JTO.0b013e318279e942.
4
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.表皮生长因子受体 - 酪氨酸激酶抑制剂(EGFR-TKI)联合贝伐单抗用于表皮生长因子受体(EGFR)突变的非小细胞肺癌的再挑战治疗
Cancer Chemother Pharmacol. 2015 Oct;76(4):835-41. doi: 10.1007/s00280-015-2867-8. Epub 2015 Sep 8.
5
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.厄洛替尼治疗的 EGFR 外显子 19 突变型非小细胞肺癌患者的异质性耐药机制:持续存在的 FGFR3 突变、局部转化为 EGFR 突变型小细胞肺癌,以及获得性 T790M EGFR 突变。
Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1.
6
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.NF-κB 驱动的 EHD1 改善有助于 EGFR 突变型肺癌对厄洛替尼的耐药性。
Cell Death Dis. 2018 Apr 1;9(4):418. doi: 10.1038/s41419-018-0447-7.
7
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.阿帕替尼增强了表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)对具有EGFR-TKI耐药性的非小细胞肺癌的抗肿瘤活性。
Eur J Cancer. 2017 Oct;84:184-192. doi: 10.1016/j.ejca.2017.07.037. Epub 2017 Aug 17.
8
DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin.DDX17 核质穿梭通过激活 β-连环蛋白促进非小细胞肺癌细胞获得吉非替尼耐药性。
Cancer Lett. 2017 Aug 1;400:194-202. doi: 10.1016/j.canlet.2017.02.029. Epub 2017 Mar 1.
9
Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT.香烟烟雾提取物暴露通过介导Src激活和上皮-间质转化诱导EGFR突变的非小细胞肺癌对EGFR-TKI耐药。
Lung Cancer. 2016 Mar;93:35-42. doi: 10.1016/j.lungcan.2015.12.007. Epub 2015 Dec 30.
10
Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.E-钙黏蛋白/β-连环蛋白复合体的改变预测表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗反应不良。
Ann Surg Oncol. 2013 Dec;20 Suppl 3:S545-52. doi: 10.1245/s10434-013-2970-1. Epub 2013 Apr 12.

引用本文的文献

1
CD146: a promising target in respiratory diseases.CD146:呼吸系统疾病中一个有前景的靶点。
Eur Respir Rev. 2025 Aug 6;34(177). doi: 10.1183/16000617.0228-2024. Print 2025 Jun.
2
The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer.植物源天然产物作为酪氨酸激酶途径调节剂在肺癌治疗中的作用
Curr Issues Mol Biol. 2025 Jun 30;47(7):498. doi: 10.3390/cimb47070498.
3
CD146 regulates the stemness and chemoresistance of hepatocellular carcinoma via JAG2-NOTCH signaling.
CD146通过JAG2-NOTCH信号通路调节肝细胞癌的干性和化疗耐药性。
Cell Death Dis. 2025 Mar 3;16(1):150. doi: 10.1038/s41419-025-07470-x.
4
CD146, a therapeutic target involved in cell plasticity.CD146,一种涉及细胞可塑性的治疗靶点。
Sci China Life Sci. 2024 Aug;67(8):1563-1578. doi: 10.1007/s11427-023-2521-x. Epub 2024 Apr 9.
5
CD146-targeted nuclear medicine imaging in cancer: state of the art.癌症中靶向CD146的核医学成像:现状
View (Beijing). 2023 Oct;4(5). doi: 10.1002/VIW.20220085. Epub 2023 Mar 1.
6
CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway.CD146 通过抑制 DCBLD2 降解并激活 AKT 通路促进乳腺叶状肿瘤的恶性进展。
Cancer Commun (Lond). 2023 Nov;43(11):1244-1266. doi: 10.1002/cac2.12495. Epub 2023 Oct 19.
7
Tumor Microenvironmental Cytokines Drive NSCLC Cell Aggressiveness and Drug-Resistance via YAP-Mediated Autophagy.肿瘤微环境细胞因子通过 YAP 介导线粒体自噬促进非小细胞肺癌细胞侵袭和耐药性
Cells. 2023 Mar 30;12(7):1048. doi: 10.3390/cells12071048.
8
Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells.1,25-二羟基维生素D3诱导的Claudin1降低通过抑制AKT激活介导的非小细胞肺癌细胞中的癌症干细胞样特性来增强吉非替尼耐药性治疗。
Cell Death Discov. 2022 Mar 18;8(1):122. doi: 10.1038/s41420-022-00918-5.
9
CD146 as a Prognostic-Related Biomarker in ccRCC Correlating With Immune Infiltrates.CD146作为与免疫浸润相关的ccRCC预后相关生物标志物
Front Oncol. 2021 Dec 8;11:744107. doi: 10.3389/fonc.2021.744107. eCollection 2021.
10
Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer.草药和生物活性化合物克服了非小细胞肺癌中对表皮生长因子受体抑制剂的耐药性。
Oncol Lett. 2021 Sep;22(3):646. doi: 10.3892/ol.2021.12907. Epub 2021 Jul 8.